NFATc1 Regulates PD-1 Expression upon T Cell Activation

Cited by (415)

Items 401–415 of 415

1. Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
   Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai · 2026 · MedComm
2. Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation
   Qingyan Zhang, Chunhui Yuan, Lin Zhu, Shaobing Zheng, Yantao Xu, 车炫霖, Shiyu Xiao, Juan Liu, Liu Hong, Hui Li et al. · 2026 · Molecular Cancer
3. Nuclear factor of activated T cells as a driver of tumor progression and a target for precision therapy
   Hira Khan, Khushbakhat Alia, Yusra Al Dhaheri, Muhammad Naseem, Rabah Iratni, Edgar Serfling, Khalid Muhammad · 2026 · Animal Models and Experimental Medicine
4. Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment
   Peilin Liu, Guoyong Han, Zhiqiang Chen, Jindao Wu · 2026 · Seminars in Oncology
5. Reprogramming the immunosuppressive microenvironment in MSS/pMMR colorectal cancer via synergistic pyroptosis induction and PD-L1 suppression
   Jingyi Mo, Weirui Huang, Rongrong Li, Yiqiong Xie, Lei Chang · 2026 · Frontiers in Immunology
6. Conserved CD4 T-cell responses correlate with antibody neutralization in solid organ transplant recipients after bivalent SARS-CoV-2 vaccination
   Georgia Stavrakis, Katerina Roznik, Laila Stoddart, Trevor Scott Johnston, Snigdha Panda, Camille Hage, Aura T. Teles, Yolanda J. Eby, William A. Werbel, Aaron A.R. Tobian et al. · 2026 · Frontiers in Immunology
7. Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies
   Nathan K. Chen, Kathryn D. Hok, Narsi Chokshi, Anthony Shadid, Haydn E. Rich, Lavanya Gunamalai, Marie–Françoise Doursout, Nirmal K. Banda, Pooja Shivshankar · 2026 · Frontiers in Cardiovascular Medicine
8. Immune Checkpoint Inhibitors: Mechanisms and Emerging Challenges
   Gurpreet Singh Gill, Subhradip Karmakar, Sandeep Goswami · 2026 · Springer eBooks
9. PD-1+/PD-L1+macrophages across diseases: a translational continuum from biomarkers to immunotherapeutic targets
   Jinjing Wu, Dan Zhou, Kunpeng Jiang, Zhenkui Li, Jiawei Ouyang, Lianyu Feng, Zhuoqi Liu, Daya Luo · 2026 · Biochemical Pharmacology
10. Fatty Acid Metabolism Rewires Glioblastoma Progression and Treg-Mediated Immune Resistance
    Nowreen Islam Chowdhury, Heba A. Ewida, Mahmoud Salama Ahmed, Heidi Villalba · 2026 · Cancers
11. Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology
    Fabiana De Franco, Marco Greppi, Valentina Obino, Federico Rebaudi, Rayan Goda, Irene Caffa, Matteo Bozzo, Ombretta Melaiu, Enrico Munari, Valerio Gaetano Vellone et al. · 2026 · Frontiers in Cell and Developmental Biology
12. Armoring CAR-T Cells Against Exhaustion: Engineering Strategies for Glioblastoma
    Ali Anvarian, Fatemeh S.M. Nazari, Ali Karimi-Jashni · 2026 · Journal of Immunotherapy
13. Sprayable hydrogel loaded with engineered fusion cellular vesicles for cancer recurrence suppression
    Yang Yumiao, Yuyue Zhao, Guowang Cheng, Zhou Lan, Hao Cui, Wei Liu, Bowen Li, Jiaxian Yu, Zhen Tian, Zhiyang Zhu et al. · 2026 · Journal of Nanobiotechnology
14. Ras protein activator-like 3 is a key Ras GTPase-activating protein that protects the survival and anti-tumor activity of CD8+ T cells
    Zhenzi Peng, Xinyi Zhou, Alato Okuno, Derick K. Okwan-Duodu, Suguru Saito · 2026 · Frontiers in Immunology
15. T-cell dysregulation in systemic lupus erythematosus: a four-layered model from extracellular cues to epigenetic remodeling and therapeutic opportunities
    Xiaoyi Zheng, Hongrui Liu, Yongkang Chen, Yunyang Wang, Shiqing Zhao, Deju Anna Kong, Dingge Cao, 崔丽艳, Wenzhe Si · 2026 · Autoimmunity Reviews